Your browser doesn't support javascript.
loading
Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model.
Sinka, Lucia; Abraira, Laura; Imbach, Lukas L; Zieglgänsberger, Dominik; Santamarina, Estevo; Álvarez-Sabín, José; Ferreira-Atuesta, Carolina; Katan, Mira; Scherrer, Natalie; Bicciato, Giulio; Terziev, Robert; Simmen, Cyril; Schubert, Kai Michael; Elshahabi, Adham; Baumann, Christian R; Döhler, Nico; Erdélyi-Canavese, Barbara; Felbecker, Ansgar; Siebel, Philip; Winklehner, Michael; von Oertzen, Tim J; Wagner, Judith N; Gigli, Gian Luigi; Serafini, Anna; Nilo, Annacarmen; Janes, Francesco; Merlino, Giovanni; Valente, Mariarosaria; Zafra-Sierra, María Paula; Bayona-Ortiz, Hernan; Conrad, Julian; Evers, Stefan; Lochner, Piergiorgio; Roell, Frauke; Brigo, Francesco; Bentes, Carla; Peralta, Ana Rita; Pinho E Melo, Teresa; Keezer, Mark R; Duncan, John S; Sander, Josemir W; Tettenborn, Barbara; Koepp, Matthias J; Galovic, Marian.
Affiliation
  • Sinka L; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Abraira L; Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Imbach LL; Swiss Epilepsy Center, Klinik Lengg, Zurich, Switzerland.
  • Zieglgänsberger D; Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
  • Santamarina E; Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Álvarez-Sabín J; Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Ferreira-Atuesta C; Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Katan M; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Scherrer N; Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.
  • Bicciato G; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Terziev R; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Simmen C; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Schubert KM; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Elshahabi A; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Baumann CR; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Döhler N; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Erdélyi-Canavese B; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Felbecker A; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Siebel P; Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
  • Winklehner M; Specialist Clinic for Neurorehabilitation, Kliniken Beelitz, Beelitz-Heilstätten, Germany.
  • von Oertzen TJ; Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
  • Wagner JN; Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
  • Gigli GL; Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
  • Serafini A; Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.
  • Nilo A; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Janes F; Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.
  • Merlino G; Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.
  • Valente M; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Zafra-Sierra MP; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Bayona-Ortiz H; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Conrad J; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Evers S; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Lochner P; Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.
  • Roell F; Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogotá, Colombia.
  • Brigo F; Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogotá, Colombia.
  • Bentes C; Department of Neurology, University of Muenster, Muenster, Germany.
  • Peralta AR; Department of Neurology and German Center for Vertigo and Balance Disorders-IFB-LMU, Ludwig Maximilians University of Munich, Munich, Germany.
  • Pinho E Melo T; Department of Neurology, University of Muenster, Muenster, Germany.
  • Keezer MR; Department of Neurology, Krankenhaus Lindenbrunn, Coppenbrügge, Germany.
  • Duncan JS; Department of Neurology, Saarland University Medical Center, Homburg, Germany.
  • Sander JW; Department of Neurology, Saarland University Medical Center, Homburg, Germany.
  • Tettenborn B; Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano-Meran, Italy.
  • Koepp MJ; Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
  • Galovic M; Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
JAMA Neurol ; 80(6): 605-613, 2023 06 01.
Article in En | MEDLINE | ID: mdl-37036702
Importance: Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk. Objective: To compare mortality and risk of epilepsy following different types of acute symptomatic seizures. Design, Setting, and Participants: This cohort study analyzed data acquired from 2002 to 2019 from 9 tertiary referral centers. The derivation cohort included adults from 7 cohorts and 2 case-control studies with neuroimaging-confirmed ischemic stroke and without a history of seizures. Replication in 3 separate cohorts included adults with acute symptomatic status epilepticus after neuroimaging-confirmed ischemic stroke. The final data analysis was performed in July 2022. Exposures: Type of acute symptomatic seizure. Main Outcomes and Measures: All-cause mortality and epilepsy (at least 1 unprovoked seizure presenting >7 days after stroke). Results: A total of 4552 adults were included in the derivation cohort (2547 male participants [56%]; 2005 female [44%]; median age, 73 years [IQR, 62-81]). Acute symptomatic seizures occurred in 226 individuals (5%), of whom 8 (0.2%) presented with status epilepticus. In patients with acute symptomatic status epilepticus, 10-year mortality was 79% compared with 30% in those with short acute symptomatic seizures and 11% in those without seizures. The 10-year risk of epilepsy in stroke survivors with acute symptomatic status epilepticus was 81%, compared with 40% in survivors with short acute symptomatic seizures and 13% in survivors without seizures. In a replication cohort of 39 individuals with acute symptomatic status epilepticus after ischemic stroke (24 female; median age, 78 years), the 10-year risk of mortality and epilepsy was 76% and 88%, respectively. We updated a previously described prognostic model (SeLECT 2.0) with the type of acute symptomatic seizures as a covariate. SeLECT 2.0 successfully captured cases at high risk of poststroke epilepsy. Conclusions and Relevance: In this study, individuals with stroke and acute symptomatic seizures presenting as status epilepticus had a higher mortality and risk of epilepsy compared with those with short acute symptomatic seizures or no seizures. The SeLECT 2.0 prognostic model adequately reflected the risk of epilepsy in high-risk cases and may inform decisions on the continuation of antiseizure medication treatment and the methods and frequency of follow-up.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Status Epilepticus / Stroke / Epilepsy / Ischemic Stroke Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male Language: En Journal: JAMA Neurol Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Status Epilepticus / Stroke / Epilepsy / Ischemic Stroke Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male Language: En Journal: JAMA Neurol Year: 2023 Document type: Article Affiliation country: Country of publication: